The present invention relates combination treatments in cancer therapy. Specifically, it provides the combination of EGFR-targeted immunoliposomes and colony-stimulating factors. The immunoliposomes preferably comprise an encapsulated cytostatic agent and an EGFR-targeting ligand such as an antibody, antibody fragment, or conjugate thereof. The colony-stimulating factors are selected from the group of granulocyte colony-stimulating factors, such as filgrastim, lenograstim, or pegfilgrastim. The immunoliposomes and the colony-stimulating factor may be administered separately or in a single composition.
